Antibody Inhibition of Human Cytomegalovirus Spread in Epithelial Cell Cultures

Overview

Journal J Virol Methods

Specialty Microbiology

Date 2013 May 15

PMID 23669101

Citations 27

Authors

Xiaohong Cui

Ronzo Lee

Stuart P Adler

Michael A McVoy

Affiliations

Soon will be listed here.

Abstract

Anti-cytomegalovirus (CMV) antibodies reduce the incidence of CMV transmission and ameliorate the severity of CMV-associated disease. Neutralizing activity, measured as the ability of antibodies to prevent entry of cell-free virus, is an important component of natural immunity. However, in vivo CMV amplification may occur mainly via spread between adjacent cells within tissues. Thus, inhibition of cell-to-cell spread may be important when evaluating therapeutic antibodies or humoral responses to infection or immunization. In vitro CMV cell-to-cell spread is largely resistant to antibodies in fibroblast cultures but sensitive in endothelial cell cultures. In the present study antibodies in CMV hyperimmuneglobulin or seropositive human sera inhibited CMV cell-to-cell spread in epithelial cell cultures. Spread inhibition activity was quantitated with a GFP reporter assay employing GFP-tagged epithelialtropic variants of CMV strains Towne or AD169. Measurement of spread inhibition provides an additional parameter for the evaluation of candidate vaccines or immunotherapeutics and to further characterize the role of antibodies in controlling CMV transmission and disease.

Citing Articles

Inhibition of human cytomegalovirus entry into mucosal epithelial cells.

He L, Hertel L, James C, Morgan I, Klingelhutz A, Fu T Antiviral Res. 2024; 230:105971.

PMID: 39074588 PMC: 11408113. DOI: 10.1016/j.antiviral.2024.105971.

Neutralizing Antibodies Limit Cell-Associated Spread of Human Cytomegalovirus in Epithelial Cells and Fibroblasts.

Reuter N, Kropff B, Britt W, Mach M, Thomas M Viruses. 2022; 14(2).

PMID: 35215877 PMC: 8875165. DOI: 10.3390/v14020284.

Peptide Derivatives of Platelet-Derived Growth Factor Receptor Alpha Inhibit Cell-Associated Spread of Human Cytomegalovirus.

Braun B, Fischer D, Laib Sampaio K, Mezger M, Stohr D, Stanton R Viruses. 2021; 13(9).

PMID: 34578361 PMC: 8473290. DOI: 10.3390/v13091780.

The Molecular Tweezer CLR01 Inhibits Antibody-Resistant Cell-to-Cell Spread of Human Cytomegalovirus.

Brenner S, Braun B, Read C, Weil T, Walther P, Schrader T Viruses. 2021; 13(9).

PMID: 34578265 PMC: 8472163. DOI: 10.3390/v13091685.

Targeted mutagenesis on PDGFRα-Fc identifies amino acid modifications that allow efficient inhibition of HCMV infection while abolishing PDGF sequestration.

Feldmann S, Grimm I, Stohr D, Antonini C, Lischka P, Sinzger C PLoS Pathog. 2021; 17(3):e1009471.

PMID: 33780515 PMC: 8031885. DOI: 10.1371/journal.ppat.1009471.

References

Jacobson M, Adler S, Sinclair E, Black D, Smith A, Chu A . A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). Vaccine. 2009; 27(10):1540-8. DOI: 10.1016/j.vaccine.2009.01.006. View

Macagno A, Bernasconi N, Vanzetta F, Dander E, Sarasini A, Revello M . Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol. 2009; 84(2):1005-13. PMC: 2798344. DOI: 10.1128/JVI.01809-09. View

Nigro G, Adler S, Parruti G, Anceschi M, Coclite E, Pezone I . Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy--a case-control study of the outcome in children. J Infect Dis. 2011; 205(2):215-27. DOI: 10.1093/infdis/jir718. View

Adler S . Editorial commentary: Primary maternal cytomegalovirus infection during pregnancy: do we have a treatment option?. Clin Infect Dis. 2012; 55(4):504-6. DOI: 10.1093/cid/cis425. View

Alberola J, Tamarit A, Navarro D . Functional antibody response to human cytomegalovirus in immunocompetent and HIV-1 infected individuals with antibodies that inhibit virus penetration into cells and intercellular transmission of viral infection. J Med Microbiol. 1999; 48(10):947-954. DOI: 10.1099/00222615-48-10-947. View

Adler B, Scrivano L, Ruzcics Z, Rupp B, Sinzger C, Koszinowski U . Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. J Gen Virol. 2006; 87(Pt 9):2451-2460. DOI: 10.1099/vir.0.81921-0. View

Cui X, McGregor A, Schleiss M, McVoy M . The impact of genome length on replication and genome stability of the herpesvirus guinea pig cytomegalovirus. Virology. 2009; 386(1):132-8. PMC: 2693885. DOI: 10.1016/j.virol.2008.12.030. View

Jiang X, Laib Sampaio K, Ettischer N, Stierhof Y, Jahn G, Kropff B . UL74 of human cytomegalovirus reduces the inhibitory effect of gH-specific and gB-specific antibodies. Arch Virol. 2011; 156(12):2145-55. DOI: 10.1007/s00705-011-1105-x. View

Digel M, Laib Sampaio K, Jahn G, Sinzger C . Evidence for direct transfer of cytoplasmic material from infected to uninfected cells during cell-associated spread of human cytomegalovirus. J Clin Virol. 2006; 37(1):10-20. DOI: 10.1016/j.jcv.2006.05.007. View

10.

Maidji E, Percivalle E, Gerna G, Fisher S, Pereira L . Transmission of human cytomegalovirus from infected uterine microvascular endothelial cells to differentiating/invasive placental cytotrophoblasts. Virology. 2002; 304(1):53-69. DOI: 10.1006/viro.2002.1661. View

11.

Fouts A, Chan P, Stephan J, Vandlen R, Feierbach B . Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol. 2012; 86(13):7444-7. PMC: 3416310. DOI: 10.1128/JVI.00467-12. View

12.

Adler S, Nigro G . Findings and conclusions from CMV hyperimmune globulin treatment trials. J Clin Virol. 2009; 46 Suppl 4:S54-7. DOI: 10.1016/j.jcv.2009.08.017. View

13.

Nigro G, Adler S, Gatta E, Mascaretti G, Megaloikonomou A, La Torre R . Fetal hyperechogenic bowel may indicate congenital cytomegalovirus disease responsive to immunoglobulin therapy. J Matern Fetal Neonatal Med. 2012; 25(11):2202-5. DOI: 10.3109/14767058.2012.684111. View

14.

Adler S, Starr S, Plotkin S, Hempfling S, Buis J, Manning M . Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis. 1995; 171(1):26-32. DOI: 10.1093/infdis/171.1.26. View

15.

Wang D, Bresnahan W, Shenk T . Human cytomegalovirus encodes a highly specific RANTES decoy receptor. Proc Natl Acad Sci U S A. 2004; 101(47):16642-7. PMC: 534536. DOI: 10.1073/pnas.0407233101. View

16.

La Torre R, Nigro G, Mazzocco M, Best A, Adler S . Placental enlargement in women with primary maternal cytomegalovirus infection is associated with fetal and neonatal disease. Clin Infect Dis. 2006; 43(8):994-1000. DOI: 10.1086/507634. View

17.

Mothes W, Sherer N, Jin J, Zhong P . Virus cell-to-cell transmission. J Virol. 2010; 84(17):8360-8. PMC: 2918988. DOI: 10.1128/JVI.00443-10. View

18.

Visentin S, Manara R, Milanese L, Da Roit A, Forner G, Salviato E . Early primary cytomegalovirus infection in pregnancy: maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age. Clin Infect Dis. 2012; 55(4):497-503. DOI: 10.1093/cid/cis423. View

19.

Navarro D, Paz P, Tugizov S, Topp K, La Vail J, Pereira L . Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells. Virology. 1993; 197(1):143-58. DOI: 10.1006/viro.1993.1575. View

20.

Sattentau Q . Avoiding the void: cell-to-cell spread of human viruses. Nat Rev Microbiol. 2008; 6(11):815-26. DOI: 10.1038/nrmicro1972. View